CA2173857A1 - Therapeutic agents - Google Patents

Therapeutic agents

Info

Publication number
CA2173857A1
CA2173857A1 CA002173857A CA2173857A CA2173857A1 CA 2173857 A1 CA2173857 A1 CA 2173857A1 CA 002173857 A CA002173857 A CA 002173857A CA 2173857 A CA2173857 A CA 2173857A CA 2173857 A1 CA2173857 A1 CA 2173857A1
Authority
CA
Canada
Prior art keywords
triazolo
ethyl
pyrimidine
formula
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002173857A
Other languages
English (en)
French (fr)
Inventor
David John Heal
Maria Isabel Fernandez Fernandez
Bruce Jeremy Sargent
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Abbott GmbH and Co KG
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2173857A1 publication Critical patent/CA2173857A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
CA002173857A 1993-10-13 1994-10-12 Therapeutic agents Abandoned CA2173857A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9321162.1 1993-10-13
GB939321162A GB9321162D0 (en) 1993-10-13 1993-10-13 Therapeutic agents

Publications (1)

Publication Number Publication Date
CA2173857A1 true CA2173857A1 (en) 1995-04-20

Family

ID=10743505

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002173857A Abandoned CA2173857A1 (en) 1993-10-13 1994-10-12 Therapeutic agents

Country Status (31)

Country Link
US (1) US5753665A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EP (1) EP0723546B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP (1) JPH09503771A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CN (1) CN1040537C (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AT (1) ATE188966T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AU (1) AU679573B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BG (1) BG62405B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BR (1) BR9407812A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CA (1) CA2173857A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CZ (1) CZ106996A3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DE (1) DE69422724T2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DK (1) DK0723546T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ES (1) ES2142413T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
FI (1) FI961630A7 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
GB (1) GB9321162D0 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
GR (1) GR3032480T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
HU (1) HUT74580A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IL (1) IL111259A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IN (1) IN179169B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
MY (1) MY112110A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NO (1) NO306509B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NZ (1) NZ274500A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PL (1) PL177920B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PT (1) PT723546E (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
RO (1) RO117020B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
RU (1) RU2136684C1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
SK (1) SK282329B6 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
TW (1) TW372237B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
UA (1) UA42738C2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
WO (1) WO1995010521A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ZA (1) ZA947949B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9506382D0 (en) * 1995-03-29 1995-05-17 Boots Co Plc Pharmaceutical compositions
GB9507348D0 (en) * 1995-04-08 1995-05-31 Knoll Ag Therapeutic agents
US5714607A (en) * 1995-12-01 1998-02-03 American Cyanamid Company Process improvement in the synthesis of N- 3-(3-cyano-pyrazolo 1,5-a!pyrimidin-7-yl)phenyl!-N-ethylacetamide
CZ18199A3 (cs) 1996-07-25 1999-06-16 Merck Sharp And Dohme Limited Triazolopyridazinové deriváty, způsob výroby a farmaceutický prostředek
GB9617727D0 (en) 1996-08-23 1996-10-02 Knoll Ag Process
GB9626746D0 (en) * 1996-12-23 1997-02-12 Knoll Ag Process
DE19706337A1 (de) * 1997-02-19 1998-08-20 Basf Ag Verfahren zur Herstellung von enantiomerenreinen Estern
DE19706336A1 (de) * 1997-02-19 1998-08-20 Basf Ag Verfahren zur Herstellung von enantiomerenreinen Alkoholen
DE19707008A1 (de) * 1997-02-21 1998-08-27 Basf Ag Verfahren zur Herstellung von enantiomerenreinen Alkoholen
AU760688B2 (en) * 1998-10-16 2003-05-22 Merck Sharp & Dohme Limited Pyrazolo-triazine derivatives as ligands for GABA receptors
GB9906126D0 (en) * 1999-03-18 1999-05-12 Knoll Ag Pharmaceutical formulations
GB9906124D0 (en) * 1999-03-18 1999-05-12 Knoll Ag Therapeutic agent
GB9906130D0 (en) * 1999-03-18 1999-05-12 Knoll Ag Compounds for use in therapy
GB9914743D0 (en) * 1999-06-24 1999-08-25 Knoll Ag Therapeutic agents
HK1052646A1 (zh) * 2000-06-30 2003-09-26 Wyeth 替代三氮苯(triazolopyrimidines)作为抗癌剂
TWI334868B (en) * 2003-06-03 2010-12-21 Nippon Kayaku Kk [1,2,4] triazoro [1,5-a] pyrimidine-2-ylurea derivative and use thereof
WO2005080320A1 (en) 2004-02-13 2005-09-01 Warner-Lambert Company Llc Androgen receptor modulators
EP1737813A1 (en) 2004-04-13 2007-01-03 Warner-Lambert Company LLC Androgen modulators
BRPI0509980A (pt) 2004-04-22 2007-10-16 Warner Lambert Co moduladores de androgênio
TW200724139A (en) 2005-05-05 2007-07-01 Warner Lambert Co Androgen modulators
PL2328414T3 (pl) 2008-08-29 2014-05-30 Concert Pharmaceuticals Inc Podstawione pochodne triazolo-pirydazyny
EP2414364A1 (en) * 2009-04-01 2012-02-08 NeuroSearch A/S SUBSTITUTED Ý1,2,4¨TRIAZOLOÝ1,5-a¨PYRIMIDINES AND THEIR USE AS POTASSIUM CHANNEL MODULATORS
US8685987B2 (en) 2009-04-01 2014-04-01 Ataxion, Inc. Substituted [1,2,4]triazolo[1,5-a]pyrimidines and their use as potassium channel modulators
WO2010112486A1 (en) * 2009-04-01 2010-10-07 Neurosearch A/S SUBSTITUTED [1,2,4]TRIAZOLO[1,5-a]PYRIMIDINES AND THEIR USE AS POTASSIUM CHANNEL MODULATORS
WO2020231723A1 (en) 2019-05-13 2020-11-19 Ecolab Usa Inc. 1,2,4-triazolo[1,5-a] pyrimidine derivative as copper corrosion inhibitor

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE46306B1 (en) * 1977-02-11 1983-05-04 Ici Ltd Safeguarded toxic chemical compositions containing an emetic
FR2549834B1 (fr) * 1983-07-25 1985-10-18 Sanofi Sa Derives de triazolo-pyrimidine, leur procede de preparation et leur application therapeutique en tant que tonicardiaques
WO1989001478A1 (en) * 1987-08-07 1989-02-23 The Australian National University ARYLOXY- AND ARALKYLTHIO-IMIDAZO[1,2-b]PYRIDAZINES
US5387747A (en) * 1992-02-24 1995-02-07 Laboratoires Upsa Triazolopyrimidine derivatives which are angiotensin II receptor antagonists, their methods of preparation and pharmaceutical compositions in which they are present

Also Published As

Publication number Publication date
PL177920B1 (pl) 2000-01-31
DE69422724T2 (de) 2000-09-07
FI961630A0 (fi) 1996-04-12
RU2136684C1 (ru) 1999-09-10
US5753665A (en) 1998-05-19
AU7855494A (en) 1995-05-04
WO1995010521A1 (en) 1995-04-20
IL111259A (en) 1998-02-08
MY112110A (en) 2001-04-30
HUT74580A (en) 1997-01-28
JPH09503771A (ja) 1997-04-15
BG100485A (bg) 1996-11-29
SK282329B6 (sk) 2002-01-07
BG62405B1 (bg) 1999-10-29
BR9407812A (pt) 1997-05-06
PL313970A1 (en) 1996-08-05
EP0723546A1 (en) 1996-07-31
NO961435D0 (no) 1996-04-11
UA42738C2 (uk) 2001-11-15
NO306509B1 (no) 1999-11-15
PT723546E (pt) 2000-04-28
ZA947949B (en) 1996-01-23
EP0723546B1 (en) 2000-01-19
RO117020B1 (ro) 2001-09-28
DE69422724D1 (de) 2000-02-24
CZ106996A3 (en) 1996-09-11
GR3032480T3 (en) 2000-05-31
IN179169B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 1997-09-06
IL111259A0 (en) 1995-03-30
NO961435L (no) 1996-06-10
NZ274500A (en) 1997-06-24
CN1135754A (zh) 1996-11-13
ATE188966T1 (de) 2000-02-15
ES2142413T3 (es) 2000-04-16
GB9321162D0 (en) 1993-12-01
HU9600959D0 (en) 1996-06-28
SK43796A3 (en) 1996-10-02
CN1040537C (zh) 1998-11-04
FI961630A7 (fi) 1996-04-12
DK0723546T3 (da) 2000-05-01
AU679573B2 (en) 1997-07-03
TW372237B (en) 1999-10-21

Similar Documents

Publication Publication Date Title
US5753665A (en) Therapeutic agents
KR100539143B1 (ko) 인돌 유도체 및 그의 5-ht2b 및 5-ht2c 수용체리간드로서의 용도
JP4963671B2 (ja) 糖尿病の治療または予防のためのジペプチジルペプチダーゼ−iv阻害剤としてのアミノシクロヘキサン
HU227830B1 (hu) 1,2-Difenil-pirrol-származékok, alkalmazásuk és ilyeneket tartalmazó gyógyászati készítmények
US5905079A (en) 1,2,4-triazolo 4,3-b!pyridazine derivatives and their use
FR2576901A1 (fr) Nouveaux derives de l'acide a-(oxo-2 hexahydro-2,4,5,6,7,7a thieno (3,2-c) pyridyl-5) phenyl acetique, leur procede de preparation et leur application therapeutique
IL228630A (en) Compounds for the treatment of metabolic syndrome and intermediates for the synthesis of these compounds
WO1996020936A1 (en) Novel thiazolidin-4-one derivatives
FR2520742A1 (fr) 1,3,4-thiadiazolo(3,2-a)pyrimidines substituees utiles comme medicaments et procede de leur preparation
AU625915B2 (en) Synthesis of (1)-benzothiopyrano (4,3-c)-pyrazoles
EP0434070A2 (en) Pyrrolealdehyde derivative
HU193360B (en) Process for producing /amino-pyridinyl/- and /nitro-pyridinyl/-amino-phenyl/-aryl-methanone derivatives
EP0231138A1 (fr) Dérivés d'acylaminométhyl-1imidazo [1,2-a] quinoléines, leur préparation et leur application en thérapeutique
FR2523972A1 (fr) Derives vinyliques substitues de la 1h-pyrazolo-(1,5-a) pyrimidine utiles notamment comme medicaments antiulcerigenes et antisecretoires gastriques et procede de leur preparation
EP1183257A1 (en) Triazolopyrimidinol compounds and salts thereof
CA3236951A1 (en) Synthetic cannabinoid compounds, pharmaceutical compositions, and treatment methods
IE910287A1 (en) Therapeutic agents
WO1993003036A1 (en) BENZOPYRANO[4,3-c]PYRAZOLES, THEIR PREPARATION AND THEIR USE AS IMMUNOMODULATORS
SK58995A3 (en) Nitric spirocyclic compounds, method of their production pharmaceutical agents which contains thereof and their use
FR2855520A1 (fr) Nouveaux derives d'imidazoles, leur preparation et leur utilisation en tant que medicament

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued